Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nanometer grainy and mucosal immunity of antiatherosclerosis nucleic vaccine

An atherosclerotic nucleic acid, mucosal immunity technology, applied in the direction of antibody medical ingredients, medical preparations containing active ingredients, allergic diseases, etc., can solve problems such as hindering the development of such vectors

Inactive Publication Date: 2005-10-12
CHINA PHARM UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Gene carriers are divided into two categories: viruses and non-viruses. Viruses, as a gene carrier with a high transfection rate, have been studied for many years, but their safety problems such as immunogenicity and tumorigenicity exposed in clinical practice hinder The further development of such vectors, in recent years, people are committed to finding safe and effective non-viral vectors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanometer grainy and mucosal immunity of antiatherosclerosis nucleic vaccine
  • Nanometer grainy and mucosal immunity of antiatherosclerosis nucleic vaccine
  • Nanometer grainy and mucosal immunity of antiatherosclerosis nucleic vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] An appropriate amount of chitosan was dissolved in 5 mM acetic acid-sodium acetate buffer solution (pH5.5) to prepare a solution with a concentration of 2 mg / ml. An appropriate amount of anti-atherosclerosis nucleic acid vaccine was dissolved in 15mM sodium sulfate solution to prepare a solution with a concentration of 500 μg / ml. Heat the above two solutions in a water bath at 55°C for 5 minutes, spin up 1 volume of the nucleic acid vaccine solution with a vortex shaker, quickly pour 0.5 volume of chitosan solution into the nucleic acid vaccine solution, and vortex for 20 seconds. Stand still at room temperature for more than 1 hour to obtain the colloidal solution of anti-atherosclerosis nucleic acid vaccine / chitosan nanoparticles.

Embodiment 2

[0021] An appropriate amount of chitosan was dissolved in 5 mM acetic acid-sodium acetate buffer solution (pH 5.5) to prepare a solution with a concentration of 300 μg / ml. An appropriate amount of anti-atherosclerosis nucleic acid vaccine was dissolved in 15mM sodium sulfate solution to prepare a solution with a concentration of 100 μg / ml. The above two solutions were heated in a water bath at 55° C. for 5 minutes, mixed rapidly with equal volumes, vortexed for 30 seconds, and left at room temperature for 1 hour to obtain a colloidal solution of anti-atherosclerotic nucleic acid vaccine / chitosan nanoparticles.

Embodiment 3

[0023] An appropriate amount of chitosan was dissolved in 5 mM acetic acid-sodium acetate buffer solution (pH5.5) to prepare a solution with a concentration of 2 mg / ml. An appropriate amount of anti-atherosclerosis nucleic acid vaccine was dissolved in 6.25mM sodium sulfate solution to prepare a solution with a concentration of 800 μg / ml. The above two solutions were heated in a water bath at 55° C. for 5 minutes, mixed rapidly with equal volumes, vortexed for 30 seconds, and left at room temperature for 1 hour to obtain a colloidal solution of anti-atherosclerotic nucleic acid vaccine / chitosan nanoparticles.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

A nanoparticle of the anti-atherosclerosis nucleic acid vaccine is rpepared from chitosan solution and the anti-atherosclerosis nucleic acid vaccine plasmid DNA through copolymerization, and features that it takes its immune effect via nasal mucosa. It can induce the generation of the specific antibody to cholesteryl ester transfer protein with high level of said antibody.

Description

technical field [0001] In the field of medicine, the anti-atherosclerosis nucleic acid vaccine / chitosan nanoparticle provided by the present invention can be conveniently applied to mucosal immunity, and the level of specific antibodies induced by the body is better than that of intramuscular injection of simple nucleic acid vaccine. Background technique [0002] Atherosclerosis (AS) is a common disease that seriously endangers human health, and its incidence is increasing significantly in our country. The occurrence of atherosclerosis is the result of multiple factors, and its etiology has not been fully elucidated. It is generally believed that cholesteryl ester transfer protein (CETP) is closely related to the occurrence and development of atherosclerosis. Nucleic acid vaccine pCR3.1-X constructed by our laboratory 8 -HBc-CETPC, through intramuscular injection, can effectively produce specific anti-CETP antibody, and can effectively prevent the occurrence of atheroscler...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/16A61K39/00A61K48/00A61P9/12A61P37/02
Inventor 宗莉顾凯龙军王学军陈伶俐曹荣月吴洁刘景晶
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com